ETONEton Pharmaceuticals, Inc.vs its industry peers
A metric-by-metric comparison of Eton Pharmaceuticals, Inc. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ETONEsta | $1.5B#7 | — | 31.4x#12 | 18.3x#7 | 104.9%#3 | -20.4%#11 | -1.1%#5 | -9.9%#7 | -1.8%#4 | 4#2 | 185.2%#2 | — |
| NUVB | $1.7B#2 | — | 6.6x#10 | 26.5x#8 | 699.0%#1 | 64.0%#6 | -338.7%#9 | -80.6%#11 | -87.4%#7 | — | -7.8%#9 | — |
| RARE | $1.7B#3 | — | — | 2.5x#3 | 20.2%#5 | -1.1%#9 | -79.5%#7 | — | — | — | -49.7%#12 | — |
| TRAX | $1.9B#1 | — | 12.8x#11 | — | — | -1.5%#10 | — | -110.0%#12 | — | — | — | — |
| KLRA | $1.6B#4 | — | 1.5x#3 | — | — | — | — | 0.0%#4 | — | — | — | — |
| ANIP | — | 15.6x#6 | — | — | 43.8%#4 | 510.5%#2 | 12.6%#3 | 13.1%#2 | 16.9%#1 | — | -23.7%#10 | — |
| INVA | $1.5B#5 | 4.9x#3 | 1.2x#2 | 3.7x#4 | 14.7%#6 | 1059.2%#1 | 39.8%#2 | 22.0%#1 | 14.7%#2 | 5#1 | 16.2%#8 | — |
| OCUL | $1.5B#6 | — | 2.9x#8 | 29.1x#9 | -18.5%#9 | -37.4%#12 | -519.8%#10 | -51.1%#10 | — | — | -39.6%#11 | — |
| PCRX | $1.5B#8 | 104.0x#7 | 2.2x#4 | 2.0x#1 | 3.6%#7 | 107.0%#3 | 2.6%#4 | 1.0%#3 | 1.0%#3 | — | 64.2%#5 | — |
| ANAB | $1.4B#9 | 8.6x#4 | 135.5x#13 | 6.1x#5 | 157.0%#2 | 90.9%#5 | 96.7%#1 | -125.0%#13 | — | — | 33.1%#6 | — |
| MLYS | $1.4B#10 | — | 2.6x#6 | — | — | 13.0%#8 | — | -28.1%#8 | -41.3%#6 | — | -59.0%#13 | — |
| DMRA | $1.4B#11 | 2.9x#2 | 2.7x#7 | — | — | -878.8%#14 | — | -40.7%#9 | — | — | 230.7%#1 | — |
| KARD | $1.3B#12 | — | 2.2x#5 | — | — | — | — | 0.0%#4 | — | — | — | — |
| LBRX | $1.3B#13 | 1.8x#1 | 4.0x#9 | — | — | 60.1%#7 | — | -7.6%#6 | — | — | 154.2%#3 | — |
| OPK | $1.3B#14 | — | 1.1x#1 | 2.2x#2 | -14.9%#8 | -324.0%#13 | -19.3%#6 | -19058.1%#14 | -13.3%#5 | 4#2 | 26.5%#7 | — |
| OMER | $1.3B#15 | 10.4x#5 | — | 17.7x#6 | -34.0%#10 | 97.9%#4 | -166.4%#8 | — | -151.8%#8 | — | 151.7%#4 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-11-04.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice